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ABSTRACT 
 
Background & Aims: Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary 
disorder associated with inflammatory bowel disease (IBD). We aimed to estimate the risk of 
disease progression based on distinct clinical phenotypes in a large, international cohort of 
patients with PSC. 
 
Methods: We performed a retrospective outcome analysis of patients diagnosed with PSC from 
1980 through 2010 at 37 centers in Europe, North America, and Australia. For each patient, we 
collected data on sex, clinician-reported age at and date of PSC and IBD diagnoses, phenotypes 
of IBD and PSC, and date and indication of IBD-related surgeries. The primary and secondary 
endpoints were liver transplantation or death (LTD) and hepatopancreatobiliary malignancy, 
respectively. Cox proportional hazards models were applied to determine the effects of 
individual covariates on rates of clinical events, with time-to-event analysis ascertained through 
Kaplan-Meier estimates. 
 
Results: Of the 7121 patients in the cohort, 2616 met the primary endpoint (median time-to-
event of 14.5 years) and 721 developed hepatopancreatobiliary malignancy. The most common 
malignancy was cholangiocarcinoma (n=594); patients of advanced age at diagnosis had an 
increased incidence, compared with younger patients (incidence rate [IR]: 1.2 per 100 patient-
years for patients younger than 20 years old, 6.0 per 100 patient-years for patients 21–30 years 
old, 9.0 per 100 patient-years for patients 31–40 years old, 14.0 per 100 patient-years for 
patients 41–50 years old, 15.2 per 100 patient-years for patients 51–60 years old, and 21.0 per 
100 patient-years for patients older than 60 years). Of all patients with PSC studied, 65.5% 
were men, 89.8% had classical or large-duct disease, and 70.0% developed IBD at some point. 
Assessing the development of IBD as a time-dependent covariate, Crohn’s disease (CD) and no 
IBD (both vs ulcerative colitis [UC]) were associated with a lower risk of LTD (unadjusted 
hazard ratio [HR], 0.62; P<.001 and HR, 0.90; P=.03; respectively) and malignancy (HR, 0.68; 
P=.008 and HR, 0.77; P=.004, respectively). Small-duct PSC was associated with a lower risk 
of LTD or malignancy compared with classic PSC (HR, 0.30 and HR, 0.15, respectively; both 
P<.001). Female sex was also associated with a lower risk of LTD or malignancy (HR, 0.88; 
P=.002 and HR, 0.68; P<.001, respectively). In multivariable analyses assessing the primary 
endpoint, small-duct PSC characterized a low-risk phenotype in both sexes (adjusted HR for 
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men, 0.23; P<.001 and adjusted HR for women, 0.48; P=.003). Conversely, patients with UC 
had an increased risk of liver disease progression compared to patients with CD (HR, 1.56; 
P<.001) or no IBD (HR, 1.15; P=.002). 
 
Conclusions: In an analysis of data from individual patients with PSC worldwide, we found 
significant variation in clinical course associated with age at diagnosis, sex, and ductal- and 
IBD subtypes. The survival estimates provided might be used to estimate risk levels for patients 
with PSC and select patients for clinical trials.  
 
KEY WORDS: risk stratification, immune-mediated liver disease, autoimmune liver disease, 
cholestasis 
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INTRODUCTION 
 
Primary sclerosing cholangitis (PSC) is a chronic immune-mediated liver disorder strongly 
associated with inflammatory bowel disease (IBD).1 Although rare, PSC carries an ongoing and 
disproportionate clinical need, with clinical outcomes being determined by the development of 
end-stage biliary cirrhosis and an independent risk of hepatopancreatobiliary (HPB) 
malignancy. To date, medical therapies have not been effective,8 and liver transplantation 
remains the only proven life-extending intervention, with 10 – 15% of all transplant activity in 
Europe now being performed for PSC.5–7  
 
Accurately reporting the natural history of disease remains a critical challenge not only for 
clinicians, but also industry and regulatory agencies who collectively recognise the need for 
new therapies and equally appreciate the risks and obstacles in demonstrating patient-benefit 
against the background of an orphan disease with a relatively variable, often slow clinical 
course.9 Moreover, patients seek reassurance and guidance as to their own prognosis, whereas 
clinicians wish to confidently recognize those at highest risk of poor outcomes as equally as 
they strive to reassure individuals with a more favorable prognosis. 
 
To expand upon single-center and single-country descriptors, the International PSC Study 
Group (IPSCSG) sponsored a multi-center outcome study to model the natural history of the 
disease. Our primary aim was to evaluate and report the clinical course from a large 
internationally representative PSC cohort; which included 7,121 patients seen at 37 centres 
across 17 countries, and encompassing >30-years of clinical observation, 1,696 liver 
transplants, 920 deaths and 721 incidents of HPB malignancy. In so doing we not only validate 
the presence of key phenotypic descriptors, but also determine the extent of their interaction 
and how they may impact the clinical course that patients may experience. 
  9 
PATIENTS AND METHODS 
 
Study setting and design 
We collected and analysed data from well-characterised patients diagnosed with PSC between 
January 1st 1980 and December 31st 2010, having previously attended or under current clinical 
follow-up until study completion (June 30th 2014). Any individual with an established 
diagnosis of PSC (including small-duct disease; sdPSC) in accordance with European or 
American recommendations10–12 was considered eligible for inclusion. When biochemical, 
serological, and/or histological features of autoimmune hepatitis (AIH) were evident 
concurrently or sequentially,13 the diagnosis of a PSC phenotype with AIH features (PSC/AIH 
variant) was made according to discretion of the participating center. IBD phenotypes were 
determined according to local expertise,14–16 and classified as ulcerative colitis (UC), Crohn’s 
disease (CD), or indeterminate colitis (IC), in keeping with consensus guidelines.17,18  
 
Data collection 
Identification of study participants was performed at a local level, either through a pre-existing 
and prospectively collected local PSC database; or in a retrospective manner via review of 
medical records by a named site investigator at a given institution. All individual center data 
was captured onto a multi-parametric standardised case record form formulated by the 
IPSCSG, and upon study completion amalgamated into a common ‘master’ database for 
downstream analysis. Individual clinical characteristics pertained to patient sex, clinician-
reported age at and date of diagnosis of PSC, sub-phenotype and IBD phenotype, date and 
indication of IBD-related surgical resections, date of LT, date of death and date and type of first 
HPB malignancy. Patients with sclerosing cholangitis suspected due to alternate aetiologies 
(e.g. IgG4-related disease, acquired immunodeficiency syndromes, confirmed biliary 
transporter defects) were excluded from the analysis, as were those with inadequate/unknown 
  10 
follow-up duration. Upon completion of data capture, all patient datasets were checked for 
plausibility and validity, and duplicated patient entries were removed prior to analysis. 
 
Data interpretation and analysis 
All patients were identified at time of diagnosis or during subsequent follow-up. ‘Time zero’ 
was set from point of diagnosis of first PSC phenotype, with the primary endpoint being the 
incidence rate (and associated risk) of LT, or death (LTD) in non-transplanted patients. Any 
individual not experiencing a clinical event in this regard was censored at date of last known 
follow-up. A secondary endpoint of HPB malignancy was also studied, and in this instance the 
date of first liver transplantation/death, or last date of ‘event-free’ follow-up comprised our 
censor points. Diagnosis of HPB malignancy was made according to clinical, radiological 
and/or histological findings as dictated by center-specific protocols. 
 
Categorical variables are expressed as numbers (n), with percentages in parenthesis, and 
continuous data as mean ± standard deviation (SD) unless otherwise indicated. Statistical 
comparisons between groups were performed using Pearson’s Chi-squared test. Differences in 
the means and proportions between individual groups of continuous data were assessed using 
the independent samples t-test, following Levene’s test for equality of variances.19 A p value 
less than 0.05 was considered statistically significant. 
 
Univariate and multivariable Cox proportional hazards models were fit to assess the impact of 
individual covariates on the instantaneous rate of clinical events, with time-to-event analysis 
ascertained through Kaplan-Meier estimates. Given that the development of IBD does not 
parallel that of PSC, the independent prognostic impact of IBD-phenotype was assessed 
separately as a time-fixed as well as a time-dependent covariate. All individual covariates were 
assessed for statistically significant interaction terms, including patient demographic features 
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(age and sex) and individual phenotypic descriptors for PSC and IBD subtypes separately. All 
analyses were stratified by geographical region (Australia, North America, Northern Europe, 
Central Europe, Western Europe or Southern Europe) and adjusted for year of PSC diagnosis. 
Incidence rates were calculated by the life tables’ method. Statistical analyses were performed 
with IBM SPSS Statistics 22.0 (SPSS Inc, Chicago, IL). 
 
Ethical approval 
This study was conducted in accordance with the protocol and principles of the Declaration of 
Helsinki. The study protocol was reviewed and approved by the local institutional ethical 
boards of all participating centers. 
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RESULTS 
 
Study population 
We accrued clinical data pertaining to 7,931 patients (53,983 patient-years); however, those 
with inadequate follow-up or indeterminate diagnosis of PSC were exempted from further 
analysis (Figure 1). The final patient cohort consisted of 7,121 patients; either having PSC in 
its classical form (89.8%), as small-duct disease (3.6%), or the PSC/AIH-variant (6.6%) (Table 
1). Observing the cohort in its entirety, the majority of patients were men (65.5%), with a mean 
age at diagnosis of 37 years versus 40 years in women (p<0.001). Seventy percent of all 
patients developed concomitant IBD prior to, at, or following PSC diagnosis; which under most 
circumstances was morphologically consistent with UC. However, the development of UC was 
less common in women than men (48.1% vs. 61.0%, respectively; p<0.001), and in those with 
variant PSC sub-phenotypes relative to classical PSC (frequency of UC in patients with 
classical PSC: 58.1% vs. 33.5% in sdPSC, and vs. 47.7% in PSC/AIH; p<0.001 for both 
pairwise comparisons) (Supplementary Tables 1, 2 and 3). 
 
During the defined observation period, 20.2%, 37.0%, 52.3% and 63.6% of patients underwent 
liver transplantation or died at 5, 10, 15 and 20 years, respectively (Figure 1), yielding a 
median transplant-free survival time of 14.5 years (95% confidence interval [CI]: 13.6 – 15.2 
years; Figure 2A). With regard to our secondary endpoint, 7.1%, 10.9%, 16.0% and 21.6% of 
the patient population developed a HPB malignancy at the aforementioned time points (Figure 
2B) (overall n = 721).  
 
The majority of HPB malignancy events were cholangiocarcinoma (CCA) (n = 594), and over 
one-third of all malignancies were detected in the first year following PSC diagnosis. The 
incidence of CCA increased with advancing age at PSC diagnosis (Supplementary Figure 1); 
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whilst hepatocellular carcinoma (n = 59) or gallbladder carcinoma (n = 58) were less frequent. 
Only ten patients across seven centers were diagnosed with pancreatic carcinoma. HPB 
malignancy developed most often in association with classical PSC, with only a small number 
of such events occurring in patients with sdPSC (1 CCA, 2 HCC, 1 pancreatic carcinoma) or 
PSC/AIH variants (12 CCA, 1 gallbladder carcinoma, 1 HCC). Overall, the development of 
HPB malignancy at any point during the clinical course was associated with a significantly 
increased risk of patient mortality (hazard ratio [HR]): 15.7, 95% CI: 14.12 – 17.34; p<0.001). 
 
Clinical stratifiers for liver transplantation/death and HPB malignancy 
The incidence rates of clinical events according to baseline phenotypic descriptors are provided 
in Supplementary Tables 4 and 5. By univariate analysis, older age at diagnosis was 
associated with significantly poorer transplant-free survival; whereas female sex, CD (relative 
to UC), and sdPSC (relative to classical PSC) were identified as being protective 
(Supplementary Table 6A). No significant difference in transplant-free survival was observed 
between the PSC/AIH variant versus the classical PSC sub-phenotype (Supplementary Figure 
2A), although patients with the former were at a low risk of developing HPB malignancy 
(Supplementary Figure 2B) (Supplementary Table 6B). 
 
The number of patients with IBD increased during our observation period (from 3469 patients 
at baseline to 4985 patients by the end of our study). Given that intestinal disease onset did not 
necessarily parallel that in the liver, the impact of IBD was subsequently determined as a time-
dependent covariate. In this context, both CD and an absence of IBD carried stratification 
properties of a lower risk PSC phenotype; whereas patients developing UC were at highest risk 
for disease progression, or future development of HPB malignancy (Supplementary Table 6). 
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Patient sex modifies the risk of liver disease progression in classical PSC 
To verify the relative independence of predictive phenotypic features, a comparative 
multivariable evaluation was performed. Through multivariable Cox regression analysis the 
prognostic impact of advancing age at diagnosis, as well as protective influences of female sex, 
having small duct disease, or CD at time of PSC diagnosis, all retained statistical significance 
in terms of stratifying risk of liver disease progression (Figures 3 and 4). 
 
Despite both factors being proven as independent risk-predictors, there was a statistically 
significant interaction (p=0.013) between patient sex and PSC sub-phenotypes when evaluating 
liver transplantation/death as an endpoint. To this effect, patients with sdPSC demonstrated 
significantly improved transplant-free survival, relative to same-sex counterparts with classical 
PSC and PSC/AIH, when matched for their age at PSC diagnosis as well as baseline IBD 
phenotype (Figure 4A). These differences were retained when adjusting for the latter as a time-
dependent covariate in our multivariable analysis (Table 2A). Although women more 
commonly exhibited non-classical PSC sub-phenotypes than men, statistically significant 
differences in the risk of LTD between the sexes were retained when restricting our analyses to 
only those patients with classical PSC (Table 2B). 
 
Unlike our primary endpoint, no statistically significant interactions were evident between 
patient sex and PSC sub-phenotypes when determining future HPB risk; wherein being female 
continued to exert a small, yet independent protective effect (but not an additive one) to that 
provided by small-duct disease (Figures 3 and 4) (Table 3A and 3B).  
 
IBD phenotype as an independent predictor of clinical outcome in PSC 
Crohn’s disease (at time of PSC diagnosis) relative to UC continued to exert a protective 
influence with respect to transplant-free survival and the development of HPB malignancy, 
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irrespective of the effect exerted by sex and PSC sub-phenotype. Such impact was not 
demonstrated in the group without IBD at baseline (Figure 4). However, when addressing the 
impact of IBD as a time-dependent covariate, both CD and IBD-absence retained independent 
stratifying properties of a lower-risk PSC population (Tables 2C and 3C). No statistically 
significant interactions existed between the different IBD phenotypes, and either PSC sub-
phenotype or patient sex. 
 
Reciprocally, development of UC prior to, or that which manifest during the clinical course of 
PSC, significantly increased the risk of LTD by 56% and 15% relative to CD or IBD-absence, 
respectively (Table 2C), and of HPB malignancy by approximately 45% and 37%, respectively 
(Table 3C). Of all patients with UC, 18.0 % (n = 718) underwent colectomy before reaching a 
primary or secondary endpoint; however, no significant difference in outcome was evident in 
such individuals relative to those retaining an intact colon (HR for colectomy in terms of LTD 
and HPB malignancy: 0.90 (95% CI: 0.78 – 1.05; p = 0.187) and 0.81 (95% CI: 0.61 – 1.07; p 
= 0.14), respectively). 
 
IBD phenotype overrides the prognostic impact of patient sex 
The prognostic impact of IBD phenotype when assessed as a time-dependent variable negated 
the marginal protective influence of female sex. This means that although sex was an 
independent risk factor of both clinical endpoints statistically, there were no demonstrable 
differences in either primary or secondary outcomes between men and women when matched 
for IBD phenotype as a time-dependent variable (data not shown). Moreover, the lower 
prevalence of UC in women (Supplementary Table 1) may account partially for differences in 
liver disease progression between the sexes.  
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DISCUSSION 
 
PSC is a disease with significant clinical and societal burden, and in recognition of the hurdles 
involved in developing effective new therapies for patients, it is essential that robust 
descriptions of disease course are generated.2,3,4 In this study, we validate the critical 
importance of specific phenotypic variants (i.e., the more favourable prognosis that limited 
small-duct variants offers patients), the negative prognostic impact of ulcerative colitis on liver-
related outcomes, and the high incidence of cholangiocarcinoma in the first year following PSC 
diagnosis.22,2 In addition, it is shown that patients with PSC and overlapping AIH-features carry 
a similar risk of liver disease progression to those with a more classical PSC phenotype; 
although development of HPB malignancy appears to be a rare event in PSC/AIH-overlap, and 
also for patients with a young presenting age at PSC diagnosis. Furthermore, we were able to 
address the prognostic impact of IBD development as a time-dependent covariate, recognising 
that development of UC is a key stratifier of adverse hepatobiliary consequences in PSC. 
Conversely, IBD-absence, and CD in particular, confer prognostic favour independent of the 
other phenotypic risk factors described.  
 
To date, sex-specific variations in clinical phenotype and correlations with patient outcomes in 
PSC have lacked robust definition. Large scale studies have demonstrated the negative 
prognostic impact of male sex in patients with related disorders such as primary biliary 
cholangitis (PBC); specifically an association with treatment non-response and a higher 
incidence of HPB malignancy.23,24 As an immune-mediated disease PSC is somewhat atypical, 
with a propensity for ‘most’ patients being younger men. However, the sex-distribution of PSC 
appears more balanced if cholangiographic screening is applied to all IBD-patients irrespective 
of biochemical abnormalities or symptomatology.25 In any event, utilising the large size of the 
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IPSCSG cohort, men with classical PSC are seen to carry a slight, albeit statistically significant 
increased risk of disease progression compared with women of matched phenotype.  
 
Our analysis also demonstrates that women with PSC have a much lower prevalence of UC 
than men. This is important because IBD phenotype, particularly when determined as a time-
dependent covariate, proves to be an independent risk factor for disease progression and may 
explain the observed differences in outcome between sexes. Conversely, patients without IBD 
or those having CD are at a comparatively lower risk of developing adverse events; a finding 
suggested previously in two single center studies, which we now validate convincingly.14,16 Of 
note, the IPSCSG has recently demonstrated genetic distinctions between patients with PSC 
and IBD versus those with IBD alone.26–28 Notwithstanding efforts to better understand clinical 
outcomes, our study further supports the need to improve IBD classification in PSC, 
particularly as the intestinal phenotype is often distinct compared to classical colitis 
descriptors,15 and more so given that genetic signals in PSC/CD may be disparate to those with 
PSC/UC.28,29 Of note, our study does not capture details pertaining to the precise distribution of 
intestinal inflammation; however, prior evidence suggests that CD in PSC is invariably 
localised to the colon, with isolated ileal disease being a seldom reported finding.14,16 
 
No significant outcome differences are apparent between men and women with the variant PSC 
sub-phenotypes, and consequently patients with sdPSC irrespective of gender experience a 
relatively sedentary clinical course compared with classical PSC. Perhaps more striking, 
however, is the highly similar transplant-free survival rate seen for patients with classical PSC 
and those with the PSC/AIH variant. Accepting the caveat that PSC/AIH lacks a codified 
diagnostic criteria,30 these observations challenge the view of PSC/AIH variants imparting a 
lesser disease burden.31 Instead, our findings indicate that once overt sclerosing cholangitis has 
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manifest, liver disease may progress at a similar rate irrespective of the initial mode of disease 
presentation.  
 
We also show how development of HPB malignancy (mainly CCA) manifests as a critical 
event in the clinical course of patients, particularly with advancing age at PSC diagnosis, and 
associated with significantly diminished patient survival. It is plausible that the reason for a 
third of CCA being identified within the first year following PSC diagnosis, is due to a delay in 
the latter’s detection (length-time bias), and not being manifest until CCA is clinically overt. 
This observation highlights the need for improving CCA screening and surveillance, especially 
in high-risk PSC patients with coexisting UC. If better non-invasive surveillance methods for 
CCA surveillance became available, it could support the rationale for systematic screening for 
PSC in UC patients.25 On the contrary, patients with small duct disease, perhaps indicative of 
PSC in an earlier form or of shorter duration, carry a lower risk of developing malignancy – as 
described previously.22,2 While this observation was somewhat expected, patients with the 
PSC/AIH-variant are also noted to develop HPB malignancy infrequently. This could possibly 
be a result of a lower UC burden, 20,2,32,33 which as our data suggests, is itself an independent 
hazard for future carcinoma development. Furthermore, with only 10 cases during 51,500 
patient years of follow-up we could not validate previous reports37 of a significant increased 
incidence of pancreatic carcinomas, albeit accepting the clinical challenges that exist in 
differentiating distal cholangiocarcinomas from primary pancreatic lesions. 
 
The natural history of PSC has previously been studied by some of the participating centers 
comprising the IPSCSG (Supplementary Table 7), although these cohorts are estimated to 
constitute, at most, <50% of our current patient population. Whilst certain patient 
characteristics that we describe mirror those in population-based registries,2 ours is highly 
representative of a specialist-center PSC experience. In light of our prolonged study period, 
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transplant-center ‘designation’ and organ allocation policies have evolved significantly across 
institutions over time. Thus, it is not possible to accurately discriminate clinical outcomes 
based solely on the division between transplant versus non-transplant centers as conducted in 
other settings.2 Admittedly, we do not present a population based epidemiological study, and 
due to the fact that more than 95% of included patients derived from centers with contemporary 
liver transplant activity, a degree of referral bias cannot be discounted. This may also explain 
the relatively low prevalence of sdPSC in our cohort.  
 
Given the retrospective nature of our study, the interval frequency of repeated cholangiography 
varied between centers, therefore exhaustive surveillance imaging may not have been 
performed to exclude progression of all small duct cases to classical PSC. Similarly, there is no 
universally accepted guideline for repeated screening colonoscopy in those without IBD, hence 
we cannot discount that sub-clinical colitis may have developed in a subset of patients 
classified as having no IBD. Of note, our reported colectomy rate was 18% in patients with UC, 
which mirrors the incidence reported in single-center studies, but is lower than that observed in 
population-based cohorts and prospective multi-center registries of UC alone.34–36  
 
Our analyses were intentionally restricted to addressing the prognostic impact of well-defined 
patient phenotypes. Consequently data pertaining to laboratory variables, extent of strictures, 
intervals of surveillance imaging or specific pharmacological interventions (e.g. 
ursodeoxycholic acid and/or immunosuppression) fell outside of the current study’s remit. 
Further large-scale investigation of therapeutic impact is of critical importance, given the 
inconsistently reported effects of these agents on disease progression and malignancy risk in 
PSC. 8 Additionally, as a systematic autopsy review was not performed from all mortality cases 
it is plausible that the incidence of HPB malignancy may in fact be higher than actually 
reported,37 particularly as CCA cannot always be discriminated from more benign changes in 
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PSC.38 We are also unable to classify all causes of death in our retrospective patient cohort, 
although previous studies indicate that mortality in PSC is invariably due to liver disease or a 
complication of coexisting IBD.2,39 A further restriction due to the retrospective nature and 
prolonged follow-up period (since 1980) is the fact that serum IgG4-levels were not determined 
systematically in all patients. Therefore it is not possible to conclusively exclude IgG4 
associated cholangiopathy within a subset of our population. 
 
The IPSCSG study confirms significant phenotypic diversity across the global PSC 
patient population. The estimates provided for transplant-free survival and the lifetime 
risk of HPB malignancy, would facilitate appropriate patient counselling and also aid in 
the future evaluation of potential new approaches to malignancy screening. In a drive to 
limit heterogeneity in clinical trials, which currently group together individuals at a high-
risk of disease progression (classical PSC and UC) together with patients at intermediate 
risk (CD or IBD-absence) and low risk (sdPSC), our data underpins a collaborative effort 
to better appraise future therapeutic ventures for this orphan disease. As a clear 
consequence of our findings, future clinical trials may now be able to stratify entry 
according to a combination of precise phenotypic risk factors, limit the heterogeneity 
within studied cohorts, and provide a more objective evaluation of therapeutic efficacy in 
specific patient groups. 
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Table 1: Summary of Patient Characteristics 
No. of pts. 7121 
No. of men 4661 (65.5%) 
Age at diagnosis:  
- Mean  38.5 yrs. (SD: 15.5)  
- < 20 yrs. 940 (13.2%) 
- 21 – 30 yrs. 1508 (21.2%) 
- 31 – 40 yrs.  1617 (22.7%) 
- 41 – 50 yrs. 1435 (20.2%) 
- 51 – 60 yrs. 953 (13.4%) 
> 60 yrs. 665 (9.3%) 
- unknown 3 (0.04%) 
PSC sub-phenotype:  
 - classical PSC  6397 (89.8%) 
- small duct PSC  254 (3.6%) 
- PSC / AIH variant 470 (6.6%) 
Diagnosis year:  
- 1980 – 1984 217 (3.0%) 
- 1985 – 1989 424 (6.0%) 
- 1990 – 1994 773 (10.9%) 
- 1995 – 1999 1414 (19.9%) 
- 2000 – 2004 1802 (25.3%) 
- 2005 – 2010 2491 (35.0%) 
IBD phenotype at baseline:  
- ulcerative colitis 2761 (38.8%) 
- Crohn’s disease 595 (8.4%) 
- indeterminate colitis 113 (1.6%) 
- no IBD  3082 (43.3%) 
- unknown timing 
-unknown IBD status 
503 (7.1%) 
67 (0.9%) 
IBD phenotype at end of follow-up:  
- ulcerative colitis 3989 (56.0%) 
- Crohn’s disease 786 (11.0%) 
- indeterminate colitis 210 (2.9%) 
- no IBD  2069 (29.1%) 
- unknown IBD status 67 (0.9%) 
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Table 2: Risk Stratification of Liver Transplantation / Death by Disease Phenotype  
 
   Reference phenotype 
Adjusted hazard 
ratio (95% CI) p-value 
A)      
PSC phenotype  Male      
 Small-duct PSC  vs Classical PSC  0.23 (0.13 – 0.40) <0.001 
 PSC/AIH variant  vs Classical PSC  0.73 (0.56 – 0.94) 0.015 
 PSC/AIH variant  vs Small-duct PSC  3.18 (1.71 – 5.92) <0.001 
 Female      
 Small-duct PSC  vs Classical PSC  0.48 (0.29 – 0.77) 0.003 
 PSC/AIH variant  vs Classical PSC  1.19 (0.91 – 1.54) 0.20 
 PSC/AIH variant  vs Small-duct PSC  2.49 (1.45 – 4.27) 0.001 
B)      
Sex Classical PSC     
 Female  vs Male  0.84 (0.77 – 0.92) 0.022 
 Small-duct PSC     
 Female  vs Male  1.76 (0.84 – 3.69) 0.13 
 PSC/AIH variant     
 Female  vs Male  1.38 (0.97 – 1.97) 0.075 
C)      
IBD phenotype Crohn’s disease vs Ulcerative colitis  0.64 (0.54 – 0.75) <0.001 
 Indeterminate colitis vs Ulcerative colitis  0.94 (0.71 – 1.26) 0.69 
 No IBD vs Ulcerative colitis  0.87 (0.79 – 0.95) 0.002 
 Crohn’s disease vs no IBD  0.73 (0.62 – 0.87) <0.001 
 Indeterminate colitis vs no IBD  1.10 (0.83 – 1.48) 0.51 
  Indeterminate colitis vs Crohn’s disease  1.50 (1.09 – 2.07) 0.013 
* All analyses are stratified by geographical region of diagnosis; adjusted for calendar year and age at 
diagnosis. Inflammatory bowel disease phenotype is defined as a time dependent covariate. Hazard ratios 
for PSC sub-phenotypes are presented separately for men and women, and separately for sex are presented 
separately for PSC sub-phenotype, given the presence of a significant interaction term between gender and 
PSC sub-phenotype (p = 0.005). 
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Table 3: Stratification of Hepatopancreatobiliary Malignancy Risk by Disease Phenotype  
 
    
 
Reference phenotype 
Adjusted hazard 
ratio (95% CI) p-value 
A)      
PSC phenotype  Small-duct PSC  vs Classical PSC 0.19 (0.07 – 0.51) 0.001 
 PSC/AIH variant  vs Classical PSC 0.31 (0.17 – 0.55) <0.001 
 PSC/AIH variant  vs Small-duct PSC 1.62 (0.52 – 5.04) 0.41 
B)      
Sex Female  vs Male 0.68 (0.57 – 0.82) 0.001 
C)      
IBD phenotype Crohn’s disease vs Ulcerative colitis 0.69 (0.52 – 0.92) 0.01 
 Indeterminate colitis vs Ulcerative colitis 1.03 (0.52 – 1.75) 0.931 
 No IBD vs Ulcerative colitis 0.73 (0.61 – 0.87) <0.001 
 Crohn’s disease vs no IBD 0.96 (0.71 – 1.29) 0.77 
 Indeterminate colitis vs no IBD 1.41 (0.82 – 2.44) 0.22 
  Indeterminate colitis vs Crohn’s disease 1.48 (0.82 – 2.67) 0.20 
* All analyses stratified by geographical region of diagnosis; adjusted for calendar year and age at diagnosis. Inflammatory 
bowel disease phenotype is defined as a time dependent covariate. 
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Figure 1: Study cohort 
 
At time of analysis data were available for 7,931 patients. However, following exclusion of 
groups with an alternate diagnose or inadequate follow-up, the final study group consisted of 
7,121 patients of which 2,616 underwent liver transplantation or died, with a total of 721 
developing primary hepatopancreatobiliary malignancy. 
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Figure 2: Cumulative incidence of clinical events 
 
Kaplan-Meier estimates of [A] liver transplant (LT)-free survival rate across the patient 
population; and [B] incidence of all hepatopancreatobiliary (HPB) malignancies. Notably, 
37.8% (n = 272) of all HPB malignancies occurred in the first year of PSC diagnosis, with the 
vast majority being cholangiocarcinoma during this time (incidence rate in the first year after 
PSC diagnosis: 2.6 cases per-100 patient-years). 
 
Patients with unknown transplantation, mortality or malignancy status at time of study 
completion were excluded from respective analysis.  
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Figure 3: Impact of Patient Age and Gender on Clinical Outcome 
 
Cox plots with regard to liver transplantation (LT) or hepatopancreatobiliary (HPB) 
malignancy. All data are stratified by geographical region of referring center and year of 
diagnosis, presented according to patient age at diagnosis and weighted for patient gender, 
inflammatory bowel disease (IBD) phenotype at baseline, and PSC sub-phenotype [A + B]; or 
patient gender weighted for patient age at diagnosis, IBD phenotype at baseline, and PSC sub-
phenotype [C + D].  
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Figure 4: Impact of Variant PSC Sub-phenotypes and IBD Phenotypes on Clinical 
Outcome 
 
Cox plots with regard to liver transplantation (LT) or hepatopancreatobiliary (HPB) 
malignancy. All data are stratified by geographical region of referring center and year of 
diagnosis, presented according to PSC sub-phenotype weighted for patient age at PSC 
diagnosis, gender, and inflammatory bowel disease (IBD) phenotype at baseline [A + B]; or 
patient IBD phenotype at baseline weighted for age at PSC diagnosis, gender, and PSC sub-
phenotype [C + D].  
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7,931 pts.
n = 810:
- Last date of follow-up unknown: 110 pts.
- Inadequate follow-up (<2 months): 459 pts.
- Diagnosis unconfirmed: 32 pts.
- IgG4-associated disease: 21 pts.
- LTx prior to diagnosis: 149 pts.
- HPB malignancy prior to PSC diagnosis: 39 pts.
7,121 pts.
1o Endpoint: 
LTx / death
2o Endpoint: 
HPB malignancy
Excluded:
n = 721:
- CholangioCa: 594 pts.
- Gallbladder Ca: 58 pts. 
- HCC: 59 pts.
- Pancreatic Ca: 10 pts.
n = 2,616:
- LT: 1,696 pts.
- Death without LT: 920 pts. 
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Supplementary Table 1: Patient Characteristics by Gender * 
A) Demographics and phenotype ** 
 Men (n = 4661) Women (n = 2454) *** 
Age at diagnosis: ****   
- Mean  37 yrs. (SD: 15) 40 yrs. (SD: 16) 
- <= 20 yrs. 660 (14·2%) 278 (11·4%) 
- 21 – 30 yrs. 1065 (22·8%) 442 (18.0%) 
- 31 – 40 yrs.  1084 (23·3%) 532 (21·7%) 
- 41 – 50 yrs. 904 (19·4%) 531 (21·7%) 
- 51 – 60 yrs. 550 (11·8%) 403 (16·4%) 
> 60 yrs. 397 (8·5%) 266 (10·8%) 
PSC sub-phenotype: ****   
 - classical PSC  4231 (90·8%) 2160 (88·0%) 
- small duct PSC  158 (3·4%) 96 (3.9%) 
- PSC / AIH variant 271 (5·8%) 198 (8·1%) 
Diagnosis year:   
- 1980 – 1984 144 (3·1%) 73 (3·0%) 
- 1985 – 1989 304 (6·5%) 120 (4·9%) 
- 1990 – 1994 524 (11·2%) 248 (10·1%) 
- 1995 – 1999 937 (20·1%) 477 (19·4%) 
- 2000 – 2004 1176 (25·2%) 623 (25·4%) 
- 2005 – 2010 1576 (33·8%) 913 (37·2%) 
IBD phenotype at baseline: ****   
- ulcerative colitis 1935 (45.4%) 823 (36.0) 
- Crohn’s disease 362 (8.5%) 233 (9·5) 
- indeterminate colitis 76 (1.8%) 37 (1·6) 
- no IBD 
  
1890 (44.3%) 
 
1190 (52.1) 
 
IBD phenotype at end of follow-up: ****   
- ulcerative colitis 2818 (61.0) 1168 (48.1) 
- Crohn’s disease 466 (10·1) 318 (13.1) 
- indeterminate colitis 143 (3·1) 67 (2·8) 
- no IBD  1193 (25·5) 874 (36.0.7) 
B) Clinical events **** Incidence rate per-100-pt. yrs. (95%. C.I.) 
Liver transplantation or death 5.58 (5.34-5.82) 5.16 (4.83-5.48) 
Hepatopancreatobiliary malignancy   
- overall 1.55 (1.41-1.68) 1.10 (0.94-1.25) 
-cholangiocarcinoma 1.28 (0.86-1.71) 0.90 (0.43-1.37) 
*  Data presented as absolute number (%) unless otherwise indicated. 
** Data presented only for patients in whom complete respective data are available. 
*** Six patients did not have gender data documented 
**** Indicates statistically significant differences of covariate frequency between all subgroups listed 
(p < 0·05). 
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Supplementary Table 2: Patient Characteristics by PSC Sub-phenotype * 
A) Demographics and phenotype ** 
 Classical PSC  
(n= 6397) 
Small-duct PSC 
(n = 254) 
PSC / AIH variant 
(n = 470) 
No. of men  4232 (66·2%) 158 (62.2%) 271 (57.8%) 
Age at diagnosis:     
- Mean  39 yrs. (SD: 15·4) 37yrs. (SD: 14·8) 32 yrs. (SD: 15) 
- < 20 yrs. 779 (12·2%) 35 (13.8%) 126 (26.8%) 
- 21 – 30 yrs. 1323 (20·7%) 59 (23.2%) 126 (26.8%) 
- 31 – 40 yrs.  1456 (22·8%) 68 (26.8%) 93 (19·8%) 
- 41 – 50 yrs. 1327 (20·8%) 43 (16.9%) 65 (13·8%) 
- 51 – 60 yrs. 884 (13·8%) 32 (12.6%) 37 (7·9%) 
> 60 yrs. 625 (9·8%) 17 (6.7%) 23 (4·9%) 
Diagnosis year:     
- 1980 – 1984 213 (3.3%) 2 (0·8%) 2 (0·4%) 
- 1985 – 1989 404 (6·3%) 9 (3·5%) 11 (2·3%)  
- 1990 – 1994 723 (11·3%) 18 (7.1%) 32 (6·8%) 
- 1995 – 1999 1287 (20·1%) 47 (18·5%) 80 (17.0%) 
- 2000 – 2004 1603 (25·1%) 79 (31.1%) 120 (25·5%) 
- 2005 – 2010 2167 (33·9%) 99 (39.0%) 225 (47.9%) 
IBD phenotype at baseline:     
- ulcerative colitis 2535 (43.2%) 67 (27.9%) 159 (36.2%) 
- Crohn’s disease 545 (9.3%) 24 (10.0%) 26 (5·9%) 
- indeterminate colitis 98 (1·7%) 6 (2·5%) 9 (2.1%) 
- no IBD  2694 (45.9%) 143 (59.6%) 245 (55.8%) 
IBD phenotype at end of study:     
- ulcerative colitis 3682 (58.1%) 85 (33.5%) 222 (47·7%) 
- Crohn’s disease 718 (11·3%) 30 (11·8%) 38 (8·2%) 
- indeterminate colitis 185 (2·9%) 7 (2·8%) 18 (3·9%) 
- no IBD  1750 (27·6%) 132 (52.0%) 187 (40.2%) 
B) Clinical events ** Incidence rate per-100-pt. yrs. (95%. C.I.) 
Liver transplantation or death 5·62 (5.42 -5.83) 2·32 (1.67 – 3.00) 4·70 (3.97 – 5.43) 
Hepatopancreatobiliary malignancy    
-overall 1·52 (1.41 –1.63) 0·20 (0.00 –0.39) 0·43 (0·20 – 0·65) 
- cholangiocarcinoma 1·25 (0.90–1.60) No cases  0·37 (0·16 – 0·58) 
*  Data presented as absolute number (%) unless otherwise indicated. 
** Data presented only for patients in whom complete respective data are available. 
 Supplementary Table 3: Patient Characteristics by IBD phenotype (at baseline) * 
A) Demographics and phenotype ** 
 Ulcerative colitis 
(n = 2761) 
Crohn’s Disease 
(n= 595) 
Indeterminate 
(n = 113) 
No IBD 
(n = 3082) 
No. of men 1935 (70·2) 362 (60.8) 76 (67·3) 1890 (61·4) 
Age at diagnosis:     
- Mean  37 yrs. (SD: 15)  38 yrs. (SD: 16)  35 yrs. (SD: 14)  40 yrs. (SD: 16)  
- <= 20 yrs. 410 (14·8%) 91 (15·3%) 17 (15·0%) 350 (11·4%) 
- 21 – 30 yrs. 646 (23·4%) 125 (21·0%) 36 (31·9%) 585 (19·0%) 
- 31 – 40 yrs.  671 (24·3%) 136 (22·9%) 24 (21·2%) 660 (21·4%) 
- 41 – 50 yrs. 510 (18·5%) 116 (19·5%) 17 (15·0%) 664 (21·6%) 
- 51 – 60 yrs. 336 (12·2%) 74 (12·4%) 13 (11·5%) 452 (14·7%) 
> 60 yrs. 188 (6·8%) 53 (8·9%) 6 (5·3%) 368 (12·0%) 
PSC sub-phenotype:     
 - classical PSC  2535 (91·8%) 545 (91·6%) 98 (86·7%) 2694 (87·4%) 
- small duct PSC  67 (2·4%) 24 (4·0%) 6 (5·3%) 143 (4.6%) 
- PSC / AIH variant 159 (5·8%) 26 (4·4%) 9 (8·0%) 245 (7·9%) 
Diagnosis year:     
- 1980 – 1984 75 (2·7%) 9 (1·5%) 4 (3·5%) 91 (3·0%) 
- 1985 – 1989 166 (6·0%) 23 (3·9%) 6 (5·3%) 167 (5·4%) 
- 1990 – 1994 327 (11·8%) 41 (6·9%) 16 (14·2%) 299 (9·7%) 
- 1995 – 1999 561 (20·3%) 104 (17·5%) 15 (13·3%) 620 (20·1%) 
- 2000 – 2004 705 (25·5%) 165 (27·7%) 27 (23·9%) 783 (25·4%) 
- 2005 – 2010 927 (33·6%) 253 (42·5%) 45 (39·8%) 1122 (36·4%) 
B) Clinical events ** Incidence rate per-100-pt. yrs. (95% C.I.) 
Liver transplantation or death 5.36 (5.06-5.67) 3.89 (3.30-4.47) 4.47 (3.07-5.88) 5.82 (5.51-6.13) 
Hepatopancreatobiliary malignancy     
-overall 1.48 (1.31-1.64) 1.21 (0.88-1.55) 1.43 (0.62-2.24) 1.34 (1.19-1.50) 
- cholangiocarcinoma 1.22 (0.72-1.72) 1.02 (0.03-2.02) 1.19 (0.00-3.07) 1.11 (0.60-1.62) 
*  Data presented as absolute number (%) unless otherwise indicated. 
** Data presented only for patients in whom complete respective data are available. 
 
 
Supplementary Table 4: Incidence Rates (IR) per-100-pt. yrs. of Liver transplantation / 
Death According to Phenotype 
 
Event: liver transplantation / death 
   
 Male Female 
 UC CD IC No-
IBD 
UC CD IC No-
IBD 
Classical 
PSC  
        
IR:  5.5 4.3 4.6 6.3 5.3 3.4 5.5 5.7 
1y survival:  94% 96% 97% 92% 95% 96% 100% 94% 
5y survival:  77% 80% 82% 71% 79% 85% 73% 77% 
10y survival: 59% 67% 73% 55% 61% 72% 62% 60% 
20y survival: 30% 52% 37% 31% 23% 67% 40% 35% 
sdPSC         
IR:  2.5 0.0 0.0 2.2 2.7 4.0 0.0 2.5 
1y survival:  96% 100% 100% 99% 100% 100% 100% 95% 
5y survival:  96% 100% 100% 89% 100% 88% 100% 86% 
10y survival: 96% 100% 100% 89% 75% 88% - 80% 
20y survival: 84% - - 82% 56% - - 67% 
PSC/AIH-
overlap 
        
IR:  4.1 4.8 2.1 3.9 5.2 6.6 0.0 5.5 
1y survival:  96% 100% 100% 96% 97% 92% 100% 96% 
5y survival:  86% 92% 83% 78% 79% 61% - 81% 
10y survival: 73% 69% 83% 68% 69% 41% - 56% 
20y survival: 45% 69% - 55% 30% 41% - 29% 
 
Supplementary Table 5: Incidence Rates (IR) per-100-pt. yrs. of HPB malignancy 
According to Phenotype 
 
Event: hepatopancreatobiliary (HPB) malignancy * 
 Male Female 
UC CD IC No-IBD UC CD IC No-
IBD 
Classical PSC         
IR; 1st yr. only: 3.1 2.2 3.5 3.8 2.2 2.1 1.9 2.6 
IR; overall: 1.6 1.6 1.4 1.7 1.5 0.6 1.5 1.1 
1y survival:  96% 97% 95% 94% 97% 97% 97% 96% 
5y survival:  92% 92% 93% 90% 92% 96% 91% 92% 
10y survival: 86% 87% 93% 86% 86% 95% 78% 90% 
20y survival: 70% 73% 82% 75% 68% 95% 78% 83% 
sdPSC         
IR; 1st yr. only: 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
IR; overall: 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.5 
1y survival:  100% 100% 100% 100% 100% 100% 100% 100% 
5y survival:  100% 100% 100% 100% 100% 100% 100% 98% 
10y survival: 100% 100% 100% 100% 89% 100% - 92% 
20y survival: 100% - - 100% 89% - - 92% 
PSC/AIH-
overlap 
        
IR; 1st yr. only: 1.5 6.5 0.0 0.7 0.0 0.0 0.0 0.8 
IR; overall: 0.7 2.0 0.0 0.2 0.2 1.2 0.0 0.1 
1y survival: 96% 92% 100% 99% 100% 100% 100% 99% 
5y survival:  94% 81% 100% 98% 98% 89% - 99% 
10y survival: 94% 81% 100% 98% 98% 89% - 99% 
20y survival: 94% 81% - 98% 98% - - 99% 
* For HPB malignancy, IR are provided for events in the 1st year only as well as overall 
 
 Supplementary Table 6: Univariate Risk Factors for Disease Progression * 
Risk factor Crude Hazard Ratio (95% C.I.) p value 
 
A) Liver transplantation / death 
Age at diagnosis ** 1·022 (1·019 – 1·025)  < 0·0001 
Gender   
Male 1 (reference)  
Female  0·88 (0·81– 0·96) 0·002 
PSC sub-phenotype    
- classical PSC 1 (reference)  
- small duct PSC 0·30 (0·21 – 0·42) < 0·001 
- PSC / AIH variant 0.81 (0·0.68 – 0.96) 0.015 
IBD phenotype (baseline)   
- ulcerative colitis  1 (reference)  
- Crohn’s disease 0.64 (0.53 – 0.76) <0.0001 
- indeterminate 0.86 (0.61 – 1.22) 0·40 
- no IBD 1.01 (0·93 – 1·10) 0·89 
IBD phenotype  
(prior-to-endpoint) *** 
  
- ulcerative colitis  1 (reference)  
- Crohn’s disease 0·62 (0·52 – 0·72) < 0·001 
- indeterminate 0·91 (0·68 – 1·21) 0·52 
- no IBD 0·90 (0·83 – 0·99) 0·03 
 
B) Hepatopancreatobiliary malignancy 
Age at diagnosis ** 1·03 (1·03 – 1·04) < 0·001 
Gender   
Male 1 (reference)  
Female  0·68 (0·57 – 0·80) < 0·001 
PSC biliary phenotype    
- classical PSC 1 (reference)  
- small duct PSC 0·15 (0·06 – 0·40) < 0·001 
- PSC / AIH variant 0·26 (0·15 – 0·44) < 0·001 
IBD phenotype  
(baseline) 
  
- ulcerative colitis  1 (reference)  
- Crohn’s disease 0·73 (0·54 – 0.96) 0·04 
- indeterminate 1·09 (0·61 – 1·94) 0·77 
- no IBD 0·88 (0·75 – 1·04) 0·14 
IBD phenotype  
(prior-to-endpoint) *** 
  
ulcerative colitis  1 (reference)  
- Crohn’s disease 0·68 (0·51 – 0·91) 0·008 
- indeterminate 0·94 (0·55 – 1·61) 0·82 
- no IBD 0·77 (0·65 – 0·92) 0·004 
*All analysis stratified by geographical region of participating centre and adjusted by patient year of diagnosis. 
** Per 1-yr. increase in age. 
*** Assessed as a time-dependent covariate 
 Supplementary Table 7: Previously published clinical outcome studies in PSC * 
Geographical location Study type  Study period or last reported 
follow-up date 
– previously reported 
Maximum No. pts.  
 
– previously reported 
Multi-national 
Italy, Norway, Spain, Sweden, UK  Observational  1998 1,2 394 
Scandinavia Clinical trial 2009 3–5 219 ** 
Finland, the Netherlands, Norway, UK Investigative 
biomarker  
2012 6 305  
Germany and Sweden Observational 1989 – 2008 (Germany) 7,8 
1992 – 2005 (Sweden)  
345 
Germany and Norway Observational 2014 11 638 
Germany and Norway Investigative 
biomarker  
2006 – 2015 (Germany) 12 
2008 – 2012 (Norway) 
318 
Belgium    
Leuven Observational 1975 – 2012 13,14 240 
Canada 
Toronto, ON Observational 2009 15 168 
France 
Paris Observational 2008 16 150 
Germany 
Heidelberg  Observational / 
investigative 
biomarker  
2012 17–21 281 *** 
Hannover Observational 200610 273 
Hamburg and Hannover Observational 20139 509 
Italy    
Multi-regional Observational 1994 22 117  
The Netherlands    
Multi-regional Observational  2008 23–27 590 *** 
Sweden    
Multi-regional Observational 1992 28 305 
Stockholm Observational 1970 – 2004 29–31 604 
USA 
Multi-regional  Clinical trial 2009 32–34 150 
Multi-regional  Observational  1995 – 2005 33 784 
Minnesota Observational  1970 – 1997 36,37 174 
California Observational  2000 – 2006 38 169 
UK 
London Observational 2011 39 128 
London Observational 1990 – 2009 40 96 
London Observational 1972 – 1989 41 169 
* Comprises PSC cohorts ~ / >100 patients, which have contributed data to the international PSC Study Group (IPSCSG). Presented reports are likely to 
include those wherein more than one publication stems from a given cohort. 
** Includes post-hoc outcome analysis of patients included in prior clinical trials. 
*** Includes a subset of patients subject to an open-label study of endoscopic biliary intervention. 
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